JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, G. P.
Right arrow Articles by Pasternak, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, G. P.
Right arrow Articles by Pasternak, G. W.

Vol. 286, Issue 1, 376-381, July 1998

3H-Naloxone Benzoylhydrazone Binding in MOR-1-Transfected Chinese Hamster Ovary Cells: Evidence for G-Protein-Dependent Antagonist Binding1

George P. Brown and Gavril W. Pasternak

The Cotzias Laboratory of Neuro-Oncology (G.P.B., G.W.P.), Memorial Sloan-Kettering Cancer Center and Departments of Neurology and Neuroscience (G.P.B., G.W.P.) and Pharmacology (G.W.P.), Cornell U. Medical College, New York, New York

Naloxone benzoylhydrazone (NalBzoH) is a potent mu antagonist in vivo. In a cell line stably transfected with MOR-1 (CHO/MOR-1), NalBzoH also was an antagonist when examined in adenylyl cyclase studies. In binding studies, it displayed high affinity for the mu receptor, confirming its earlier characterization in brain membranes. In competition studies under equilibrium conditions, NalBzoH and diprenorphine both retained their potency in the presence of the stable GTP analog 5'-guanylylimidophosphate, consistent with their mu antagonist properties, whereas the agonist DAMGO showed more than a 3-fold loss of affinity. The dissociation of H-diprenorphine was monophasic. However, kinetic studies revealed biphasic dissociations for both 3H-NalBzoH and 3H-DAMGO. The slow component of 3H-NalBzoH dissociation, corresponding to the higher affinity state, was dependent on coupling to G-proteins. It is selectively abolished by guanine nucleotides, leaving only the rapid dissociation phase. Furthermore, the slow dissociation component is eliminated by treatment of the cells with pertussis toxin, but not cholera toxin. In conclusion, NalBzoH is an unusual opioid. Functionally it is an antagonist, a classification consistent with its equilibrium binding in the presence of guanine nucleotides. Yet, kinetic studies reveal that it labels a G-protein coupled state of the receptor with high affinity.

0022-3565/98/2861-0376$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
C. P. Fitzsimons, F. Monczor, N. Fernandez, C. Shayo, and C. Davio
Mepyramine, a Histamine H1 Receptor Inverse Agonist, Binds Preferentially to a G Protein-coupled Form of the Receptor and Sequesters G Protein
J. Biol. Chem., August 13, 2004; 279(33): 34431 - 34439.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. D. Alves, Z. Salamon, E. Varga, H. I. Yamamura, G. Tollin, and V. J. Hruby
Direct Observation of G-protein Binding to the Human {delta}-Opioid Receptor Using Plasmon-Waveguide Resonance Spectroscopy
J. Biol. Chem., December 5, 2003; 278(49): 48890 - 48897.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G.-M. Zhao, X. Qian, P. W. Schiller, and H. H. Szeto
Comparison of [Dmt1]DALDA and DAMGO in Binding and G Protein Activation at {micro}, {delta}, and {kappa} Opioid Receptors
J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 947 - 954.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
F. Monczor, N. Fernandez, B. L. Legnazzi, M. E. Riveiro, A. Baldi, C. Shayo, and C. Davio
Tiotidine, a Histamine H2 Receptor Inverse Agonist That Binds with High Affinity to an Inactive G-Protein--Coupled Form of the Receptor. Experimental Support for the Cubic Ternary Complex Model
Mol. Pharmacol., August 1, 2003; 64(2): 512 - 520.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. Christopoulos and T. Kenakin
G Protein-Coupled Receptor Allosterism and Complexing
Pharmacol. Rev., June 1, 2002; 54(2): 323 - 374.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
G. Chen, J. Way, S. Armour, C. Watson, K. Queen, C. K. Jayawickreme, W.-J. Chen, and T. Kenakin
Use of Constitutive G Protein-Coupled Receptor Activity for Drug Discovery
Mol. Pharmacol., January 1, 2000; 57(1): 125 - 134.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
R. Seifert, U. Gether, K. Wenzel-Seifert, and B. K. Kobilka
Effects of Guanine, Inosine, and Xanthine Nucleotides on beta 2-Adrenergic Receptor/Gs Interactions: Evidence for Multiple Receptor Conformations
Mol. Pharmacol., August 1, 1999; 56(2): 348 - 358.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.